This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO)

Tipranks - Tipranks - Thu Jun 18, 6:38AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO) with bullish sentiments.

Claim 55% Off TipRanks

Axsome Therapeutics (AXSM)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Axsome Therapeutics today and set a price target of $258.00. The company’s shares closed last Tuesday at $251.91.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 12.7% and a 59.2% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. ;'>

Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $266.69, representing a 4.6% upside. In a report issued on June 3, TipRanks – Google also upgraded the stock to Buy with a $250.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Guardian Pharmacy Services, Inc. Class A (GRDN)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Guardian Pharmacy Services, Inc. Class A, with a price target of $47.00. The company’s shares closed last Tuesday at $42.42.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.9% and a 58.8% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., Ardent Health Partners, Inc., and Aveanna Healthcare Holdings. ;'>

Currently, the analyst consensus on Guardian Pharmacy Services, Inc. Class A is a Strong Buy with an average price target of $46.75, an 8.4% upside from current levels. In a report issued on June 12, TipRanks – OpenAI also upgraded the stock to Buy with a $48.00 price target.

Alto Neuroscience, Inc. (ANRO)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alto Neuroscience, Inc. today and set a price target of $50.00. The company’s shares closed last Tuesday at $21.00.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 21.3% and a 49.4% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Precision BioSciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alto Neuroscience, Inc. with a $34.78 average price target, implying a 63.7% upside from current levels. In a report issued on June 15, JonesTrading also reiterated a Buy rating on the stock with a $44.00 price target.

Read More on AXSM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).